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Neurobiology of Disease
Amyloid  Oligomers Disrupt Blood–CSF Barrier Integrity
by Activating Matrix Metalloproteinases
Marjana Brkic,1,2,5* XSriram Balusu,1,2* Elien VanWonterghem,1,2Nina Gorle´,1,2 Iryna Benilova,3,4 Anna Kremer,1,2
Inge Van Hove,6 Lieve Moons,6 Bart De Strooper,3,4 Selma Kanazir,5 Claude Libert,1,2†
and XRoosmarijn E. Vandenbroucke1,2†
1Inflammation Research Center, VIB, B-9052 Ghent, Belgium, 2Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium,
3Center for the Biology of Disease, VIB, Leuven, Belgium, 4Center for Human Genetics and Leuven Institute of Neuroscience and Disease, KU Leuven,
Leuven, Belgium, 5Department of Neurobiology, Institute for Biological Research, University of Belgrade, Belgrade, Republic of Serbia, and 6Laboratory of
Neural Circuit Development and Regeneration, KU Leuven, Leuven, Belgium
The blood–CSF barrier (BCSFB) consists of a monolayer of choroid plexus epithelial (CPE) cells that maintain CNS homeostasis by
producing CSF and restricting the passage of undesirable molecules and pathogens into the brain. Alzheimer’s disease is the most
common progressive neurodegenerative disorder and is characterized by the presence of amyloid  (A) plaques and neurofibrillary
tangles in the brain. Recent research shows that Alzheimer’s disease is associated withmorphological changes in CPE cells and compro-
mised production of CSF. Here, we studied the direct effects of A on the functionality of the BCSFB. Intracerebroventricular injection of
A1–42 oligomers into the cerebral ventricles of mice, a validated Alzheimer’s disease model, caused induction of a cascade of detri-
mental events, including increased inflammatory gene expression in CPE cells and increased levels of proinflammatory cytokines and
chemokines in the CSF. It also rapidly affected CPE cellmorphology and tight junction protein levels. These changeswere associatedwith
loss of BCSFB integrity, as shown by an increase in BCSFB leakage. A1–42 oligomers also increased matrix metalloproteinase (MMP)
gene expression in the CPE and its activity in CSF. Interestingly, BCSFB disruption induced by A1–42 oligomers did not occur in the
presence of a broad-spectrum MMP inhibitor or in MMP3-deficient mice. These data provide evidence that MMPs are essential for
the BCSFB leakage induced by A1–42 oligomers. Our results reveal that Alzheimer’s disease-associated soluble A1–42 oligomers
induce BCSFB dysfunction and suggest MMPs as a possible therapeutic target.
Key words: alzheimer’s disease; amyloid  toxicity; blood–CSF barrier; choroid plexus; matrix metalloproteinases
Introduction
Alzheimer’s disease is the most common progressive form of
dementia, characterized by synaptic loss, neurodegeneration, and
impairment of cognitive function. Overproduction and de-
creased clearance of amyloid  (A) peptide, followed by forma-
tion of amyloid plaques, is believed to be the central player of
Alzheimer’s disease (Deane et al., 2009; Alvira-Botero and Carro,
2010). More than a decade ago, it was observed that progression
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Significance Statement
No treatments are yet available to cureAlzheimer’s disease; however, solubleAoligomers are believed to play a crucial role in the
neuroinflammation that is observed in this disease. Here, we studied the effect of A oligomers on the often neglected barrier
between blood and brain, called the blood–CSF barrier (BCSFB). This BCSFB is formed by the choroid plexus epithelial cells and is
important in maintaining brain homeostasis. We observed A oligomer-induced changes in morphology and loss of BCSFB
integrity thatmight play a role inAlzheimer’s disease progression. Strikingly, both inhibition ofmatrixmetalloproteinase (MMP)
activity andMMP3 deficiency could protect against the detrimental effects of A oligomer. Clearly, our results suggest thatMMP
inhibition might have therapeutic potential.
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of the disease is more strongly correlated with the presence of
soluble A than with the number of plaques (McLean et al.,
1999). This A molecular form, which is an intermediate be-
tween monomeric A and insoluble amyloid plaques, is now
recognized as important mediator in the pathology of Alzhei-
mer’s disease. Recently, it was shown that mice injected with
oligomerized A1– 42 display neuronal cell loss, tau hyperphos-
phorylation, and impairment of hippocampus-dependent mem-
ory (Brouillette et al., 2012; Ledo et al., 2013). Similarly, injection
of A1– 42 in the brain ventricles of zebrafish embryos leads to
cognitive deficits and tau hyperphosphorylation (Nery et al.,
2014).
The microenvironment in the brain is strictly maintained by
two main barriers: the blood– brain barrier (BBB) in the brain
parenchyma and the blood–CSF barrier (BCSFB) in the choroid
plexus (CP). The BBB separates brain interstitial fluid from blood
at the level of brain capillaries, which are formed by endothelial
cells connected through tight junctions, restricting paracellular
transport. In addition, pericytes and astrocytic end feet contrib-
ute to strict insulation of the BBB (Zlokovic, 2008). In contrast,
capillaries in the CP are highly fenestrated due to the absence of
tight junctions. Therefore, the BCSFB is formed by CP epithelial
(CPE) cells that are firmly interconnected by tight junctions sep-
arating blood from CSF. CPE cells also contain many specific
transport systems and receptors that provide them with an active
role in the regulation of transport from blood to CSF and vice
versa. In addition, the BCSFB acts as a relay station that senses
inflammation signals from both the CNS (Batra et al., 2010;
Sharma et al., 2010; Simard et al., 2011) and the periphery
(Marques et al., 2007; Marques et al., 2009a; Marques et al.,
2009b; Vandenbroucke et al., 2012). CPE cells respond to inflam-
matory stimuli by producing proinflammatory molecules, which
is often associated with disturbance of barrier integrity and re-
sults in transmission of the inflammatory signals to the rest of the
brain (Mitchell et al., 2009; Coisne and Engelhardt, 2011) and
increased white blood cell influx into the brain (Demeestere et al.,
2015).
Alzheimer’s disease is associated with numerous changes in
CP morphology and function, of which the most prominent are
decreased CSF production, changes in metabolic activity, and
reduced clearance of toxins, including A (Serot et al., 2000;
Serot et al., 2003; Emerich et al., 2005; Krzyzanowska and Carro,
2012; Serot et al., 2012; Marques et al., 2013; Spector and Johan-
son, 2013). In addition, the vascular system of the brain is com-
promised (Zlokovic, 2011). Recent studies suggest that one of the
possible causes of BBB disruption in Alzheimer’s disease is degen-
eration and loss of pericytes (Sagare et al., 2013; Winkler et al.,
2014). Breakdown of the endothelial and epithelial barriers has
been linked to increased activity of matrix metalloproteinases
(MMPs), endopeptidases that are implicated in several inflam-
matory processes (Vandenbroucke and Libert, 2014) and are
known to affect tight junction functionality and extracellular ma-
trix composition, eventually aggravating brain inflammation
(Zeni et al., 2007; Batra et al., 2010; Vandenbroucke et al., 2012).
Several studies have suggested that MMPs play a role in Alzhei-
mer’s disease pathogenesis (Wang et al., 2014). For example, CSF
and brain MMP levels are higher in Alzheimer’s disease patients
than in age-matched controls and MMPs have been implicated in
degradation of A (Guo et al., 2006; Yan et al., 2006; Yin et al.,
2006; Hanzel et al., 2014; Kauwe et al., 2014; Mroczko et al.,
2014). Here, we studied the direct toxic effects of A1– 42 oli-
gomers on the functionality of the CPE.
Materials andMethods
Mice. Female C57BL/6 mice (8 –10 weeks old) were purchased from Jan-
vier and housed in our specific pathogen-free (SPF) animal facility.
MMP3-deficient mice (Mudgett et al., 1998) in the C57BL/6 background
were bred in our SPF facility (MMP3/). Mice were housed in groups
of 4 – 6/cage with ad libitum access to food and water and a 14 h light/10
h dark cycle. All experiments were approved by the ethics committee of
the Faculty of Sciences of Ghent University.
Preparation of A1–42 oligomers. Oligomerized A1– 42 was prepared
as described previously (Kuperstein et al., 2010; Brouillette et al., 2012).
Briefly, A1– 42 (rPeptide; A-1163-1) or scrambled A1– 42 (rPeptide;
A-1004-1) was dissolved at 1 mg/ml in hexafluoroisopropanol (HFIP;
Sigma-Aldrich; catalog #105228), followed by HFIP removal in a Speed-
Vac vacuum concentrator. The resulting peptide film was resolved at 1
mg/ml in DMSO (Sigma-Aldrich; catalog #D4540). Next, the peptide
was purified from DMSO on a 5 ml HiTrap desalting column (GE
Healthcare; catalog #17-408-01) and eluted with Tris-EDTA buffer (50
mM Tris and 1 mM EDTA, pH 7.5). The resulting peptide concentration
was determined using the Thermo Scientific–Pierce Micro BCA Protein
Assay (catalog #23225) according to the manufacturer’s instructions.
Finally, the eluted peptide was allowed to aggregate for 2 h at room
temperature and then diluted to 1 g/ml in Tris-EDTA buffer. To con-
firm the oligomer formation, we characterized the freshly prepared
A1– 42 oligomers by analyzing Thioflavin T incorporation into aggre-
gates, performing dot blot analysis, atomic force microscopy analysis,
Coomassie-stained SDS-PAGE gel analysis, and cell toxicity assays as
described previously (data not shown; Brouillette et al., 2012).
Injection of A1–42 oligomers and scrambled peptide in the cerebral
ventricles. Animals were anesthetized with isoflurane and placed in a
stereotactic frame. Body temperature was maintained at 37°C using a
heating pad. Injection coordinates were measured from the bregma (an-
teroposterior0.07, mediolateral 0.1, dorsoventral0.3) and were de-
termined using the Franklin and Paxinos mouse brain atlas. A volume of
5 l (1 g/ml peptide) was injected in the right lateral cerebral ventricle
using a Hamilton needle. To assess the role of MMPs, we used three
treatments: A1– 42 oligomers (in Tris-EDTA buffer) combined with 1
g of broad spectrum MMP inhibitor (GM6001; Merck; CC1100) dis-
solved in DMSO, A1– 42 oligomers (in Tris-EDTA buffer) combined
with DMSO and vehicle for the control group.
BCSFB and BBB permeability. BCSFB and BBB permeability were de-
termined as described previously (Vandenbroucke et al., 2012). In brief,
4 kDa FITC-dextran (Sigma-Aldrich; catalog #46944) was injected intra-
venously 1 h before CSF collection. Two and 6 h after A1– 42 oligomer
injection, mice were sedated with ketamine/xylazine and CSF was ob-
tained from the fourth ventricle using the cisterna magna puncture
method (Liu and Duff, 2008). Next, mice were transcardially perfused
with D-PBS/heparin (0.2% heparin) and brain tissue was isolated. CSF
samples were diluted 100-fold in sterile D-PBS and BCSFB leakage was
determined by measurement of fluorescence at ex/em  488/520 nm.
Brain samples were cut into small pieces, incubated overnight at 37°C in
formamide while shaking, and supernatant was collected after centrifu-
gation for 15 min at maximal speed. Brain fluid was diluted twofold in
sterile D-PBS and BBB leakage was determined by measurement of fluo-
rescence at ex/em 488/520 nm.
Tissue isolation. For RNA and protein analysis, mice were transcardi-
ally perfused with D-PBS/heparin (0.2% heparin) supplemented with
0.5% bromophenol blue. Brain tissue was dissected out, CP was obtained
from all four ventricles, and hippocampus was isolated. Isolated hip-
pocampus was kept in RNAlater (Ambion; catalog #AM7020) and CP
was snap frozen in liquid nitrogen. For immunohistochemical analysis,
brain was immediately frozen in cryoprotectant (Thermo Scientific; cat-
alog #4583) and stored at80°C for cryosectioning or fixed in 4% para-
†C.L. and R.E.V. contributed equally to this work.
Correspondence should be addressed to Dr. Roosmarijn Vandenbroucke, VIB Ghent University, FSVM Building,
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formaldehyde (PFA) followed by paraffin embedding for paraffin
sections.
Immunohistochemistry. For Occludin and Claudin-5 immunostaining
of cryosections, 30 m sagittal sections were cut using a cryostat (Mi-
cron; catalog #HM500) and mounted on slides. After air drying for 2 h,
sections were fixed with 1% PFA for 10 min, washed for 5 min in PBS, and
permeabilized for 10 min with 0.1% NP-40. After 2 washes with PBS,
samples were blocked for 1 h at room temperature with 5% BSA (Sigma-
Aldrich; catalog #A2153) and then incubated with primary antibody
(Life Technologies; Occl, 1:100, 33–1500; Cldn5, 1:50, 35–2500). After
incubation overnight at 4°C, they were washed and incubated with sec-
ondary antibody (Thermo Scientific; goat anti-mouse-DyLight633 and
goat anti-rabbit-DyLight633, 1:400) diluted in 5% BSA for 90 min at
room temperature (RT). For E-cadherin and Iba1 staining, paraffin-
embedded brains were sectioned at 4 m in sagittal orientation, dew-
axed, and rinsed in water and PBS before staining. Antigen retrieval was
done using citrate buffer (Dako; catalog #S2031), followed by washing in
PBS. For E-cadherin staining, slides were incubated overnight at 4°C with
0.01 M NaBH4 (Sigma-Aldrich; catalog #452882) to further reduce auto-
fluorescence. After rinsing in PBS, permeabilization was done with
0.05% Tween-20 (Sigma-Aldrich; catalog #P1379) for 30 min at RT.
Samples were blocked with 2% BSA for 30 min at RT, followed by incu-
bation for 90 min at RT with primary (E-Cadherin, 1:500; BD Transduc-
tion Laboratories; catalog #610181) and secondary antibodies (; Alexa
Fluor 568 goat anti-mouse, 1:500; Life Technologies) diluted in 5% BSA.
For Iba-1 staining, antigen retrieval was followed by overnight incuba-
tion at 4°C with primary antibody (; Iba1, 1:1000; Wako; catalog #019
19741). The next day, slides were washed and incubated with LSAB2
System HRP (DAKO; catalog #K0672) and visualization was done using
DAB chromogen. Finally, slides were dehydrated and xylene-based
mounting medium was applied. Cells were visualized using Olympus
BX51 microscope. Iba1-positive cells were counted in predefined area of
the brain, including both cortex and hippocampus, using Fiji (http://fiji.
sc/Fiji). Microglia were classified into resting and activated according to
adopted criteria (Hains and Waxman, 2006).
Cytokine/chemokine measurements. Cytokines and chemokines in CSF
were measured using the Bio-Plex cytokine assays (Bio-Rad; catalog
#M60009RDPD) according to the manufacturer’s instructions.
RNA isolation. Total RNA was isolated with the (mi)RNeasy kit
(Qiagen; catalog #74106). RNA concentration and purity were deter-
mined spectrophotometrically using the Nanodrop Technologies
ND-1000.
Real-time qPCR. After RNA isolation, cDNA was synthesized by using
a cDNA Synthesis Kit (Bio-Rad; catalog #172-5038). Real-time qPCR was
performed on the Light Cycler 480 system (Roche) using the Light-
Cycler 480 SYBR Green I Master mix (Roche; catalog #04887352001) or
the SensiFAST SYBR No-ROX Kit (Bioline; catalog #BIO-98002). Ex-
pression levels were normalized to the expression of the two or three
most stable reference genes, as determined by the geNorm Housekeeping
Gene Selection Software (Vandesompele et al., 2002): Hprt, Rpl, and Ubc
for CP and Gapdh, Rpl, and Ubc for hippocampus. The sequences of the
forward and reverse primers for the different genes are provided in
Table 1.
MMP activity. MMP activity in the CSF was analyzed using the Omn-
iMMP fluorogenic substrate kit according to manufacturer’s guidelines
(Enzo Life Sciences; catalog #BML-AK016). In brief, CSF samples were
diluted 50-fold in assay buffer and MMP activity was determined by
measuring the increase in fluorescence at ex/em 320/460 nm.
Western blot. For Occludin Western blot analysis, CP samples from
two mice were pooled and homogenized in 50 l of lysis buffer contain-
ing 0.5% CHAPS (Sigma-Aldrich; catalog #C9426) and protease inhibi-
tor complete tablet (Roche Applied Science; catalog #11 873 580 001).
Protein concentration was determined using the Thermo Scientific–
Pierce Micro BCA Protein Assay and 60 g of proteins were loaded on a
12.5% SDS-PAGE gel. For MMP3 Western blot analysis, 2 l of each
sample, derived from scrambled and A1– 42 oligomer injected mice,
was loaded on a 12.5% SDS-PAGE gel. Further protocol remained the
same for both Occludin and MMP3 detection. Semidry transfer was
performed for 1 h at constant current (45 mA) and membranes were
blocked for 1 h using Odyssey blocking buffer (Li-Cor; catalog #927-
40000), followed by overnight incubation with primary antibody at 4°C
(anti-Occludin, 1:250, Life Technologies, catalog #33-1500; anti-MMP3,
1:100, Abcam, catalog #ac52915). Next, membranes were incubated with
the secondary antibody (Thermo Scientific anti-mouse Dylight 680,
1:1000) for 2 h at RT and bands were visualized using Odyssey software.
Serial block-face scanning electron microscopy. For serial block-face
scanning electron microscopy (SBF-SEM), CP tissue was dissected and
immediately transferred into fixation buffer (2% paraformaldehyde,
Sigma-Aldrich; 2.5% glutaraldehyde, Electron Microscopy Sciences in
0.15 M cacodylate buffer, pH 7.4). After overnight fixation at 4°C, samples
were washed 3 5 min in cacodylate buffer and subsequently osmicated
in 2% osmium (EMS), 1.5% ferrocyanide, and 2 mM CaCl2 in cacodylate
buffer for 1 h on ice, and then washed extensively in ultrapure water
(UPW). This was followed by incubation in 1% thiocarbohydrazide (20
min), washes in UPW, and a second osmication in 2% osmium in UPW
(30 min). The samples were washed 5 3 min in UPW and placed in 2%
uranyl acetate at 4°C overnight. The following day, they were stained with
Walton’s lead aspartate stain for 30 min at 60°C. For this, a 30 mM
L-aspartic acid solution was used to freshly dissolve lead nitrate (final
concentration 20 mM, pH 5.5). The solution was filtered after incubation
for 30 min at 60°C.
After the final washes, the samples were dehydrated using a series of
ice-cold solutions of increasing ethanol concentration (30%, 50%, 70%,
90%, and twice 100%), followed by two dehydrations of 30 min in 100%
acetone. Subsequent infiltration with resin (Durcupan; EMS) was done
by first incubating the samples in 50% resin in acetone for 4 h, followed
by at least 5 changes of fresh 100% resin (including 2 overnight incuba-
tions). Next, samples were embedded in fresh resin and cured in the oven
at 65°C for 72 h.
For SBF-SEM, the resin-embedded samples were mounted on an alu-
minum specimen pin (Gatan) using conductive epoxy (Circuit Works).
The specimens were trimmed in a pyramid shape using an ultrami-
crotome (Ultracut; Leica) and the block surface was trimmed until
smooth and at least a small part of tissue was present at the block face.
Next, samples were coated with 5 nm Pt in a Quorum Q 150T ES sputter
coater (Quorum Technologies). The aluminum pins were placed in the
Gatan 3View2XP in a Zeiss Merlin SEM for imaging at 1.6 kV with a
Gatan Digiscan II ESB detector. The Gatan 3view2XP was set to section
300 sections of 70 nm. IMOD (http://bio3d.colorado.edu/imod/) and
Fiji (Schindelin et al., 2012) were used for registration of the 3D image
Table 1. Overview of the sequences of the forward and reverse primers used for
qPCR analysis
Gene Forward Reverse
Il1 CACCTCACAAGCAGAGCACAAG GCATTAGAAACAGTCCAGCCCATAC
Il6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC
Tnf ACCCTGGTATGAGCCCATATAC ACACCCATTCCCTTCACAGAG
Ocln CCAGGCAGCGTGTTCCT TTCTAAATAACAGTCACCTGAGGGC
Cldn5 GCAAGGTGTATGAATCTGTGCT GTCAAGGTAACAAAGAGTGCCA
Zo1 AGGACACCAAAGCATGTGAG GGCATTCCTGCTGGTTACA
Zo3 ACCCTATGGCCTGGGCTTC CCCGGGTACAACGTGTCC
Cldn1 TCTACGAGGGACTGTGGATG TCAGATTCAGCAAGGAGTCG
Ecdh TCGGAAGACTCCCGATTCAAA CGGACGAGGAAACTGGTCTC
Mmp1a CCTTGATGAGACGTGGACCAA ATGTGGTGTTGTTGCACCTGT
Mmp2 AGATCTTCTTCTTCAAGGACCGGTT GGCTGGTCAGTGGCTTGGGGTA
Mmp3 AGTCTACAAGTCCTCCACAG TTGGTGATGTCTCAGGTTCC
Mmp8 ATTCCCAAGGAGTGTCCAAGC TGATTGTCATATCTCCAGCACTGG
Mmp9 CTGGACAGCCAGACACTAAAG CTCGCGGCAAGTCTTCAGAG
Mmp13 TTTATTGTTGCTGCCCATGA GGTCCTTGGAGTGATCCAGA
Mmp14 CAGTATGGCTACCTACCTCCAG GCCTTGCCTGTCACTTGTAAA
Rpl CCTGCTGCTCTCAAGGTT TGGTTGTCACTGCCTGGTACTT
Ubc AGGTCAAACAGGAAGACAGACGTA TCACACCCAAGAACAAGCACA
Gapdh TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGAG
Hprt AGTGTTGGATACAGGCCAGAC CGTGATTCAAATCCCTGAAGT
2M ATGCACGCAGAAAGAAATAGCAA AGCTATCTAGGATATTTCCAATTTTTGAA
act GCTTCTAGGCGGACTGTTACTGA GCCATGCCAATGTTGTCTCTTAT
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stack and conversion to TIFF file format. Rep-
resentation of the cell in 3D movies and snap-
shots was done in Imaris (BitPlane). 3D
modeling of CPE cells was performed using
IMOD software.
Statistics. Data were analyzed using Graph-
Pad Prism and Student’s t test and are pre-
sented as means SEM. Significance levels are
indicated on the graphs as follows: *0.01 p
0.05; **0.001  p  0.01; ***0.0001  p 
0.001; and ****p 0.0001.
Results
Intracerebroventricular administration
of A1–42 oligomers induces
inflammation in brain, CP, and CSF
In Alzheimer’s disease, A and its deposits,
along with neurofibrillary tangles, induce a
chronic local upregulation of inflammatory
mediators (Akiyama et al., 2000). We pre-
pared A1–42 oligomers by resuspending
A1–42 peptide film in Tris-EDTA buffer
as described previously (Kuperstein et al.,
2010), followed by incubation for 2 h to al-
low oligomerization. Next, C57BL/6 mice
were injected intracerebroventricularly with
A1–42 oligomers (Brouillette et al., 2012)
and the effect on brain inflammation was
studied. Gene expression analysis of the hip-
pocampus revealed that several inflamma-
tory genes were significantly upregulated 6 h
after A1–42 oligomer injection: Il6, IL1,
and TNF levels are shown in Figure 1a–c,
respectively. In contrast, Iba1 immuno-
staining did not reveal a significant increase
in microglia activation in mice 6 h after in-
tracerebroventricular injection of A1–42
(Fig. 1e,f) compared with injection of
scrambled peptide (Fig. 1d,f). The CP is one of the sites involved in
the production, deposition, and clearance of A in the brain (Cross-
grove et al., 2005; Crossgrove et al., 2007; Krzyzanowska and Carro,
2012). To study the direct effect of A1–42 oligomers on inflamma-
tion in the CP and hippocampus, CSF, CP, and hippocampus were
isolated 2 and 6 h after intracerebroventricular injection of scram-
bled peptide or A1–42 oligomers and total RNA was extracted
from CP and hippocampus. Next, we determined mRNA levels of
several proinflammatory cytokines (Fig. 2a–h). Il1, Il6, Tnf, and
Inos were significantly upregulated 2 h after intracerebroventricular
injection of A1–42 compared with scrambled peptide. The up-
regulation was even more pronounced 6 h after intracerebroventric-
ular injection in CP (Fig. 2a–d). Similarly, we determined mRNA
levels of the proinflammatory cytokines in the hippocampus (Fig.
2e–h). As observed in the CP, there was a significant increase in the
Il1, Il6, Tnf, and InosmRNA expression at 2 h. With the exception
of iNos, these effects were more pronounced at 6 h.
Next, to determine whether this upregulation in cytokine ex-
pression was accompanied by inflammatory protein expression,
we evaluated cytokine levels in CSF using the BioPlex assay (Fig.
2i–l). The significantly increased presence of the proinflamma-
tory cytokines IL-1, IL-6, TNF, and IFN in CSF at both time
points correlated with the elevated mRNA levels observed in the
CP: they were significantly increased 2 and 6 h after intracerebro-
ventricular injection of A1– 42. In parallel, we measured several
chemokines in the CSF: MIP-1, MIP-1, MCP-1, and GM-CSF
were all upregulated at the tested time points in the presence of
A1– 42 (Fig. 2m–p).
Our data show that A1– 42 oligomers induce a strong in-
flammatory response in the brain that is more pronounced in the
CP than in the rest of the brain. This is reflected by increased
cytokine and chemokine levels in the CSF.
Intracerebroventricular injection of A1–42 oligomers
induces morphological changes in the CP and loss of BCSFB
integrity
The CP undergoes morphological alterations in Alzheimer’s dis-
ease (Marques et al., 2013). Therefore, we injected C57BL/6 mice
intracerebroventricularly with oligomerized A1– 42 and studied
CPE morphology 6 h later using SBF-SEM. This technology uses
a fully automated microtome installed in the SEM chamber to
produce serial sections that makes 3D reconstructions of SEM
samples (Denk and Horstmann, 2004) and this revealed that
A1– 42 induces loss of the typical cuboidal structure of CPE cells
(Fig. 3; Movies 1 and 2). To better visualize the differences in our
SBF-SEM images, we performed 3D modeling of CPE cells to
highlight the morphological differences. CPE cell outlines were
drawn manually using IMOD software for 200 sections per
sample. These sections were then merged to generate a 3D model
of the cell shape. CPE cells retained typical cuboidal structure
after scrambled peptide injection. In contrast, several cells in
A1– 42 oligomer-injected mice lost their cuboidal shape and the
overall cell volume was reduced compared with the scrambled
Figure 1. Analysis of inflammation in the hippocampus after intracerebroventricular injection of oligomerized A1–42 in the
cerebral ventricles. a–c, mRNA expression analysis of Il1 (a), Il6 (b), and Tnf (c) in the hippocampus 6 h after intracerebroven-
tricular injection of A1–42 in C57BL/6mice compared with control hippocampus samples (n 4). d, e, Representative images
of Iba1 staining of brain sections from C57BL/6 mice 6 h after intracerebroventricular injection with scrambled peptide (d) or
A1–42 oligomers (e). As indicated on the images, the region surrounding the lateral ventricle is represented. f, Quantification of
the percentage of activatedmicroglia in cortex andhippocampus of scrambled andA1–42oligomer injectedmice (n 5). Scale
bar, 25m.
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injected CPE cells. In addition, CPE cells in A1– 42 oligomer-
injected mice displayed reduced nucleus size (Fig. 3c,d). Next, we
analyzed whether the severe morphological changes induced by
A1– 42 oligomers affect BCSFB integrity. To compare blood–
CSF permeability in control mice and in mice injected intracere-
broventricularly with A1– 42 oligomers, we injected 4 kDa
FITC-dextran intravenously 1 h before CSF isolation and mea-
sured fluorescence in CSF. The results revealed that A1– 42
oligomers induce permeability of the BCSFB 6 h after intracere-
broventricular injection, demonstrating that oligomerized
A1– 42 disturbs CPE barrier functionality (Fig. 4a).
Subsequently, we used qPCR, Western blotting, and immu-
nostaining to determine whether the alterations in BCSFB integ-
rity induced by A1– 42 oligomers were correlated with changes
in junctional proteins in the CP. Gene expression analysis re-
vealed that several tight junction genes were affected by intrace-
rebroventricular injection of A1– 42 oligomers. As shown in
Figure 4, b and c, expression of Claudin-5 (Cldn5) and Occludin
(Ocln) was significantly downregulated in response to A1– 42
oligomers. Notably,Oclnwas significantly downregulated at both
time points tested, whereas Cldn5 was significantly downregu-
lated only 6 h after A1– 42 oligomer injection. Zona occludens-1
(Zo1) and Claudin-1 (Cldn1) were significantly downregulated
2 h after A1– 42 oligomer injection (Fig. 4e,f). In contrast, Zo3
showed no change in gene expression at that time point (Fig. 4g).
Gene expression of the adherens junctional genes E-cadherin
(Ecdh) andN-cadherin (Ncdh) was unaffected at both time points
(Fig. 4h,i). OCLN, the tight junction protein that was most se-
verely affected 6 h after intracerebroventricular injection, was
also analyzed by Western blot. CP tissue was isolated from con-
trol mice and from mice injected intracerebroventricularly with
A1– 42 oligomers and pooled samples were analyzed by SDS-
PAGE. Immunodetection revealed that OCLN protein levels are
downregulated by intracerebroventricular injection of A1– 42
oligomers (Fig. 4d). This was also studied by fluorescent immu-
nostaining. Confocal imaging revealed that, in control mice,
OCLN was enriched at the apical side of the CPE cells (Fig. 4j,k,
white arrowheads). In agreement with the Western blot analy-
sis, the OCLN signal was reduced after A1– 42 oligomer in-
jection (Fig. 4l,m, white arrowheads). We also analyzed the
adherens junction protein ECDH. Like OCLN, this protein
was enriched at the apical side of CPE cells, but it was unaf-
fected by intracerebroventricular injection of A1– 42 oli-
gomers (Fig. 4n,o). Our data show that tight junction proteins
are affected at the mRNA and/or protein level upon intracere-
Figure 2. Cytokine and chemokine analyses of CP, hippocampus, and CSF after intracerebroventricular injection of A1–42 oligomers.a–d, mRNA expression analysis of Il1 (a), Il6 (b), Tnf (c),
and Inos (d) in CP after intracerebroventricular injection of A1–42 (gray) in C57BL/6mice comparedwith control CP samples (black) (n 3–4). e–h, mRNA expression analysis of Il1 (e), Il6 (f ),
Tnf (g), and Inos (h), in thehippocampusafter intracerebroventricular injectionofA1–42 (gray) in C57BL/6mice comparedwith control samples (black) (n3–4). i–p, Levels of cytokines (IL-1,
IL-6, TNF, and IFN) and chemokines (MIP-1, MIP-1, MCP-1, and GM-CSF) in CSF isolated from C57BL/6 mice injected intracerebroventricularly with scrambled peptide (black) or A1–42
(gray) (n 4).
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Figure 3. CPmorphology analysis by SFB-SEM. a,b, Representative SBF-SEM images of CP cells of C57BL/6mice injected intracerebroventricularly with scrambled (a) or A1–42 oligomers (b).
Cell shape is outlined in green. c, d, 3D modeling (blue) based onmerging200 sections of CPE cells from scrambled (c) and A1–42 oligomer (d) injected mice. Only cell shape was considered;
basolateral labyrinth and microvilli were neglected while generating the 3D modeling. Mv, Microvilli; Nu, nucleus. Scale bar, 2m.
Movie 1. Morphology of CPE of mice after injection of scrambled peptide into the cerebral
ventricles. Shown are representative 3D reconstructions of CPE samples from C57BL/6 mice by
SFB-SEM 6 h after injection of scrambled peptide in the cerebral ventricles.
Movie 2. Morphology of the CPE of mice injected in the cerebral ventricles with A1–42
peptide. Shown are representative 3D reconstructions of CPE samples from C57BL/6 mice by
SFB-SEM 6 h after injection of A1–42 peptide in the cerebral ventricles.
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broventricular A1– 42 oligomer injection, which might ex-
plain the observed BCSFB leakage.
In parallel, we also studied the effect of A1– 42 oligomers on
BBB integrity. As shown in Figure 5a, we did not observe a sig-
nificant increase in BBB leakage 6 h after A1– 42 oligomer ad-
ministration. In addition, also Ocln, Cldn1, and Zo1 gene
expression was not affected in the hippocampus upon intracere-
broventricular injection of A1– 42 oligomers, whereas Cldn5
Figure4. AnalysisofA1–42-induceddisruptionofBCSFBintegrity.a,RelativeBCSFBpermeability2and6hafterintracerebroventricularinjectionofA1–42inthecerebralventricles(gray)comparedwithcontrolmice
(black)(n4).b,c,Ocln(b)andCldn5gene(c)expressioninCPtissueofC57BL/6miceinjectedintracerebroventricularlywithscrambled(black)orA1–42(gray)peptide(n4).d,WesternblotanalysisofOccludininCP
tissuefromC57BL/6controlmiceandmiceinjectedintracerebroventricularlywithA1–42peptide.e–i,Zo1(e),Cldn1(f ),Zo3(g),Ecdh(h),andNcdh(i)geneexpressioninCPtissueofC57BL/6miceinjectedinthecerebral
ventricleswithA1–42(gray)orscrambledpeptide(black)(n4). j–m,Representativeconfocal imagesofC57BL/6controlmice(j,k)andmiceinjectedintracerebroventricularlywithA1–42(l,m)peptidefor6h(red,
Occludin; blue, Hoechst). The arrowheads point to the apically located tight junctions. Scale bars: e,g, 50m; f,h, 10m. n 5.n,o, Representative confocal images of control (n) and A1–42 (o) peptide injected
intracerebroventricularly inC57BL/6micestainedforE-cadherin(ECDH;red)andHoechst(blue).Thearrowheadspointtoadherensjunctions.
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did show a significant decrease in gene expression compared with
scrambled peptide control (Fig. 5b–e). Clearly, intracerebroven-
tricular injection of A1– 42 oligomers only modestly affects the
BBB 6 h after the injection.
A1–42 oligomer-induced BCSFB disruption is linked to
increasedMMP expression and activity
Previous studies have shown altered expression of MMPs in Alz-
heimer’s disease patients (Wang et al., 2014) and MMPs have
been implicated in BCSFB disruption in response to TNF (Zeni et
al., 2007) and in several inflammatory conditions (Vandenb-
roucke and Libert, 2014) such as sepsis (Vandenbroucke et al.,
2012) and stroke (Batra et al., 2010). To determine whether
MMPs play a role in the A1– 42 oligomer-induced BCSFB leak-
age, we analyzed MMP gene expression in the CP and MMP
activity in the CSF. Figure 6a shows the fold changes in gene
expression of Mmp1a, Mmp2, Mmp3, Mmp8, Mmp9, Mmp13,
and Mmp14 2 h (black) and 6 h (gray) after intracerebroventric-
ular injection of A1– 42 oligomers. Mmp3 was significantly up-
regulated 2 h after intracerebroventricular injection and Mmp3,
Mmp8, Mmp9, and Mmp13 at 6 h after injection. This was asso-
ciated with an increase in MMP activity in the CSF 6 h after
A1– 42 oligomer injection (Fig. 6b). Next, we coinjected
A1– 42 oligomers intracerebroventricularly with the broad-
spectrum MMP inhibitor GM6001. The results show that inhibi-
tion of MMP activity prevented the A1– 42 oligomer-induced
BCSFB disruption. Indeed, comparison of BCSFB integrity of
mice injected with A1– 42 oligomers alone or combined with
MMP inhibitor revealed that MMP inhibition prevents oli-
gomerized A1– 42 from inducing BCSFB leakage (Fig. 6c). As
expected, this was associated with a decrease in MMP activity in
the CSF (Fig. 6b). Clearly, inhibiting MMP activity diminishes
the detrimental effects of A1– 42 oligomers. Based on the gene
expression analysis displayed in Figure 6a, we also analyzed
MMP3 protein level in the CSF. Western blot analysis clearly
showed an increase in secreted MMP3 (Fig. 6d). Finally, we in-
jected A1– 42 oligomers intracerebroventricularly in wild-type
and MMP3-deficient (MMP3/) mice to confirm the suspected
role of MMPs, especially MMP3. As shown in Figure 6e, absence
of MMP3 significantly prevented BCSFB leakage induced by
A1– 42 oligomers. In agreement with this, A1– 42 oligomers
did not affect the morphology of the CPE cells in MMP3/mice
(Fig. 7).
Discussion
Neuroinflammation occurs very early on in disease progression
and in several brain regions affected by Alzheimer’s disease. Ab-
normal molecules such as A1– 42, hyperphosphorylated tau
protein, and damaged neurons induce the activation of cyto-
kines, complement proteins, and chemokines, as well as other
acute phase pathways, eventually leading to inflammation
(Akiyama et al., 2000). In a 2004 human study, increased levels of
proinflammatory cytokines were found in plasma before the clin-
ical onset of the disease (Engelhart et al., 2004). In addition, cell
culture studies and animal models of Alzheimer’s disease dem-
onstrated that inflammation precedes the appearance of patho-
logical hallmarks of Alzheimer’s disease such as senile plaques
and neurofibrillary tangles (Floden et al., 2005; Wright et al.,
2013). Some evidence indicates that soluble A oligomers, an
intermediate between monomeric A and insoluble amyloid
plaques, are an important mediator in the inflammation and pa-
thology of Alzheimer’s disease. Although the concentration of
Figure5. Analysis of the effect of A1–42 oligomers on BBB integrity.a, Relative permeability of the BBB 6 h after intracerebroventricular injection of A1–42 oligomers (gray) comparedwith
scrambledpeptide injectedmice (black) (n10–13).b–e, Relativegeneexpressionof tight junctionproteinsOccludin (b),Claudin-5 (c),Zonaoccludens-1 (d), andClaudin-1 (e) in thehippocampus
6 h after intracerebroventricular injection of scrambled peptide (black) or A1–42 oligomers (gray) (n 5).
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soluble A1– 42 was not uniform in different studies (Nitta et al.,
1997; Kong et al., 2005; Marco and Skaper, 2006; Brouillette et al.,
2012; Cetin et al., 2013), in most, A1– 42 was able to initiate a
cascade of the events that recapitulate the key pathological hall-
marks of Alzheimer’s disease. In vitro incubation of macro-
phages, microglia, astrocytes, and oligodendrocytes with soluble
A induced inflammation (Johnstone et al., 1999; Lee et al., 2002;
Smits et al., 2002). In vivo, microvessels
forming the BBB isolated from the brains
of Alzheimer’s disease patients showed
markedly increased levels of IL-1, IL-6,
and TNF compared with control subjects
(Grammas and Ovase, 2001; Tripathy et
al., 2007).
Here, we made use of A1– 42 oligom-
ers prepare as described previously, which
are known to induce neuronal cell loss,
tau hyperphosphorylation, and impair-
ment of hippocampus-dependent mem-
ory (Brouillette et al., 2012; Ledo et al.,
2013; Nery et al., 2014). Injected A1– 42
levels werefourfold compared with lev-
els measured in transgenic APP/PS1 mice
(Maia et al., 2013). In agreement with pre-
vious studies, intracerebroventricular in-
jection of A1– 42 oligomers induced
brain inflammation, as reflected by in-
creased gene expression of Il6, Il1, and
TNF in the hippocampus, the area of the
brain crucial for memory and among
the first regions to be affected in Alzheimer’s disease. Using the
same mouse model as in our study, Kuperstein et al. (2010) found
inhibition of new memory formation 24 h after A1– 42 oligomer
injection. Because elevated cytokine levels in hippocampus are
able to induce memory impairment in rats (Czerniawski and
Guzowski, 2014), it could be speculated that elevated proinflam-
Figure 6. Analysis of the role of MMPs in A1–42-induced disruption of BCSFB permeability. a, Fold change inMmp gene expression in the CP 2 h (black) and 6 h (gray) after intracerebroven-
tricular injectionofA1–42 in the cerebral ventricles comparedwith control samples (n3–4).b, TotalMMPactivity in CSFof C57BL/6mice6hafter intracerebroventricular injectionof scrambled
peptide (control), A1–42oligomers (A), orA1–42oligomers togetherwithGM6001 (AGM6001) (n6). c, BCSFBpermeability of C57BL/6mice6hafter intracerebroventricular injection
of A1–42 oligomers alone (A) or combinedwith theMMP inhibitor GM6001 (A GM6001) comparedwith scrambled peptide injectedmice (control) (n 6–7). d, Western blot analysis of
MMP3 protein levels in CSF of control and A1–42 oligomer intracerebroventricularly injected mice. e, Relative BCSFB permeability in wild-type (black) and MMP3/ (gray) C57BL/6 mice 6 h
after intracerebroventricular injection of scrambled control or A1–42 oligomers (n 4–10).
Figure 7. CP morphology analysis by SFB-SEM of MMP3/ mice. a, b, Representative SFB-SEM images of the CPE cells of
scrambled peptide (a) and A1–42 oligomer (b) intracerebroventricularly injectedMMP3/mice. Cell shape is represented in
green. Basolateral labyrinth and microvilli were neglected while drawing the cell outline. Mv, Microvilli; Nu, nucleus.
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matory cytokine levels contribute to memory deterioration in
this model of Alzheimer’s disease.
Several studies have shown that Alzheimer’s disease is associ-
ated with morphological and functional changes at the BCSFB
(Serot et al., 2000; Serot et al., 2003; Emerich et al., 2005; Krzyza-
nowska and Carro, 2012; Serot et al., 2012; Marques et al., 2013;
Spector and Johanson, 2013). However, it is not fully understood
how the integrity of the BCSFB is affected in Alzheimer’s disease
and whether the CP is involved in triggering and/or enhancing
the inflammatory response to A. Therefore, we studied the ef-
fect of intracerebroventricular injection of A1– 42 oligomers on
the BCSFB. The BCSFB is formed by a single continuous layer of
modified cuboidal epithelium, the CPE cells, which are attached
on their basal sides to the basal lamina (Wolburg and Paulus,
2010). CPE cells are large and have a centrally positioned spher-
ical nucleus, copious cytoplasm, and plenty of apically positioned
microvilli. In addition to their barrier function, CPE cells are
responsible for the production and secretion of CSF, as well as
other biologically active components involved in nutrition, en-
docrine function, and clearance of the brain areas (Johanson et
al., 2008). Here, we show that the CP responds to intracerebro-
ventricular injection of soluble A1– 42 oligomers by increasing
its expression of the proinflammatory cytokines Il1, Il6, Tnf,
and Inos. This was associated with significantly elevated levels of
cytokines and chemokines in the CSF. One of the Alzheimer’s
disease theories proposes that monomeric and oligomeric A
activate microglia, which respond by secreting proinflammatory
cytokines, leading to the spread of inflammation, cell death, and
overall neurodegeneration (Maezawa et al., 2011; Solito and Sas-
tre, 2012). However, despite the observed increased mRNA levels
of proinflammatory cytokines in the hippocampus upon intrace-
rebroventricular injection of A1– 42 oligomers, we did not ob-
serve significant microglial activation. This indicates that the
inflammatory signal generated in the CPE in response to soluble
A1– 42 oligomers might occur before microglia activation dur-
ing the development of Alzheimer’s disease. However, we do not
exclude that the injected A1– 42 oligomers also affect other cell
types, as noted in the past by other research groups (Kopec and
Carroll, 1998; von Bernhardi and Eugenín, 2004).
Some of the reported Alzheimer’s disease-associated changes
involve CPE cell atrophy, accumulation of Biondi tangles and
lipofuscin deposits, irregular basement thickening, decreased
CSF production and secretion, and diminished capacity for clear-
ance of unwanted molecules from CSF (Emerich et al., 2005). In
our study, we observed that a single intracerebroventricular in-
jection of A1– 42 oligomers affected the cuboidal morphology
of CPE cells, suggesting that some of the observed morphological
changes at the CPE in Alzheimer’s disease occur early during
disease development.
The ability of CPE cells to restrict paracellular passage of mol-
ecules depends on the presence of junctional complexes at their
apical sides (Redzic, 2011). Several studies have shown a link
between increased cytokine levels and decreased tight junction
expression at the BBB and BCSFB (Minagar and Alexander, 2003;
Barichello et al., 2011; Chai et al., 2014). Diminished BBB integ-
rity, which leads to an increase in permeability and a decrease in
tight junction expression, was found in both mouse and human
Alzheimer’s disease studies (Romanitan et al., 2010; Biron et al.,
Figure 8. Schematic overview of direct effects of A1–42 oligomers on the BCSFB. A monolayer of CPE cells, tightly connected by tight junctions, restricts entrance of molecules from the
fenestrated capillaries into the CSF. Injection of oligomerized A1–42 into the cerebral ventricles of mice (1) leads to secretion of MMPs, cytokines, and chemokines from CPE cells into the CSF (2),
and this induces disruption of tight junctions (3), eventually resulting in BCSFB leakage.
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2011; Carrano et al., 2011; Hartz et al., 2012). In agreement with
the A1– 42 oligomer-induced cytokine increase in the CSF, we
observed that a single intracerebroventricular injection of
A1– 42 oligomers affected the gene and protein expression lev-
els of tight junctions. Furthermore, we observed increased leak-
age of fluorescently labeled dextran from blood into the CSF,
indicating that A1– 42 injection leads to loss of BCSFB integrity.
In contrast, we did not observe loss of BBB integrity 6 h after
intracerebroventricular injection of A1– 42 oligomers.
MMPs have been recognized as important players in neuro-
degenerative diseases (Rosenberg, 2009). The large family of
MMPs includes collagenases, gelatinases, stromelysins, and
membrane-type MMPs, which are expressed by endothelial, ep-
ithelial, and inflammatory cells at the different brain barriers in
response to inflammation (Vandenbroucke and Libert, 2014).
The involvement of MMPs in BCSFB breakdown has been ob-
served in various disease models (Zeni et al., 2007; Batra et al.,
2010; Vandenbroucke et al., 2012). So far, there are no data im-
plicating MMPs in the loss of BCSFB integrity during Alzheimer’s
disease. In our acute model of Alzheimer’s disease, we observed
increased mRNA levels of several MMPs associated with in-
creased MMP activity in the CSF. The A1– 42 oligomer-induced
increase was most prominent forMmp3. Importantly, the broad-
spectrum MMP inhibitor GM6001 prevented the detrimental ef-
fects of A1– 42 oligomer injection on the BCSFB, suggesting the
involvement of MMPs in A1– 42 oligomer-induced BCSFB
breakdown. Although we did not show this in our study, the
observed BCSFB dysfunction might be due to direct cleavage of
tight junction proteins, as was shown previously for several
MMPs (Nava et al., 2013), or it might also be caused by cytokine
activation or cleavage of extracellular matrix components, as we
have shown previously (Vandenbroucke et al., 2012; Vandenb-
roucke et al., 2013).
MMP3 is believed to be a key player in inflammation and is
secreted by CPE cells (Thouvenot et al., 2006). Indeed, we were
able to detect secreted MMP3 in the CSF of A1– 42 oligomer-
injected mice. Interestingly, several recent studies propose
MMP3 as a potential biomarker for Alzheimer’s disease because it
is significantly upregulated in the brain, CSF, and plasma of Alz-
heimer’s disease patients (Yoshiyama et al., 2000; Horstmann et
al., 2010; Hanzel et al., 2014; Kauwe et al., 2014; Mroczko et al.,
2014). A recent study in a mouse model of spinal cord injury
showed that MMP3-deficient mice display reduced disruption of
the blood–spinal cord barrier (Lee et al., 2014). To further study
the role of MMP3, we injected MMP3-deficient mice intracere-
broventricularly with A1– 42 oligomer and found that the ab-
sence of MMP3 strongly reduced the A1– 42 oligomer-induced
BCSFB leakage. Moreover, Mmp8, Mmp9, and Mmp13 mRNA
levels were elevated in the CP upon intracerebroventricular in-
jection of A1– 42 oligomer, so these MMPs might also play a
role in the observed loss of BCSFB integrity. In previous work, we
showed that MMP8 contributes to inflammation-induced
BCSFB leakage (Vandenbroucke et al., 2012) and MMP8
(Schubert-Unkmeir et al., 2009), MMP9 (Chiu and Lai, 2013),
and MMP13 (Vandenbroucke et al., 2013) have been linked to
tight junction dysregulation. Previously, MMP9 was shown to be
involved in BBB breakdown mediated by ApoE4 (Halliday et al.,
2013). Altogether, our data provide solid evidence for a detri-
mental role of MMPs in A1– 42 oligomer-induced BCSFB
disruption.
As schematically depicted in Figure 8, our data indicate that
A1– 42 oligomers, via CPE-derived cytokine and MMP secre-
tion, might induce BCSFB barrier breakdown early during the
development of Alzheimer’s disease, thereby contributing to en-
hancement of neuroinflammation. Indeed, loss of brain barrier
integrity might further aggravate neuroinflammation by en-
trance of undesirable molecules into the brain. It has been sug-
gested that BBB dysfunction might contribute to Alzheimer’s
disease (Erickson and Banks, 2013). Based on our results, BCSFB
dysfunction might be an even earlier event during disease devel-
opment, so further research is needed to study whether restoring
BCSFB integrity might reduce neuroinflammation during Alz-
heimer’s disease.
In conclusion, our study shows that the presence of A1– 42
oligomers in the CSF induces disruption of the BCSFB via the
production of proinflammatory cytokines and MMPs, which is
linked to loss of tight junction functionality.
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